Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Update

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 58.9% from the December 15th total of 799,400 shares. Based on an average trading volume of 171,900 shares, the short-interest ratio is currently 7.4 days. Currently, 7.4% of the shares of the company are short sold.

Hedge Funds Weigh In On Telomir Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in TELO. Barclays PLC grew its stake in Telomir Pharmaceuticals by 325.1% during the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after buying an additional 5,367 shares in the last quarter. Beaird Harris Wealth Management LLC boosted its stake in Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after buying an additional 9,950 shares in the last quarter. State Street Corp lifted its holdings in shares of Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter valued at approximately $241,000. Finally, Suncoast Equity Management boosted its position in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after buying an additional 26,803 shares in the last quarter.

Telomir Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ TELO opened at $4.79 on Friday. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72. The stock’s fifty day moving average price is $4.60 and its two-hundred day moving average price is $4.75.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.